Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00416650
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
erlotinib hydrochloride
Sponsor
Vanderbilt-Ingram Cancer Center
Collaborators
[object Object]